Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026.
Shares of StandardAero jumped 36% in the company's trading debut as the aircraft maintenance services provider raised $1.44 billion in its IPO. Additionally, Chain Bridge Bancorp opened on Oct. 5 at $22.
It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259 million to complete development of its product.
A trio of biotech companies' shares rose on Friday in their first trading sessions. Bicara Therapeutics, MBX Biosciences, and Zenas BioPharma each sold more shares in their respective initial public offerings than they had planned.
